CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cystein...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Steven JACOBS, Alastair KING, Linus HYUN, Michael DIEM, Mark ANDERSON, Donna KLEIN, Sheri MOORES, Karyn O''NEIL, Shalom GOLDBERG, Kristen PICHA, Ricardo ATTAR
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule, isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically. Moleculas que contienen el dominio de FN3 de EGFR y/o c-Met FN3 monoespecifico y biespecifico disenado de cisteina que comprenden uno o mas aminoacidos de cisteina libre se preparan al mutagenizar una secuencia de acidos nucleicos de una molecula madre y reemplazando uno o mas residuos de aminoacidos por cisteina para codificar las moleculas monoespecificas o biespecificas que contienen el dominio de FN3 disenado de cisteina; expresar las moleculas que contienen el dominio de FN3 disenado de cisteina; y recuperar la molecula que contiene el dominio de FN3 disenado de cisteina; las moleculas que contienen el dominio aislado de FN3 monoespecifico o biespecifico pueden ser unidas covalentemente a una etiqueta de deteccion o a una porcion de farmaco y usarse terapeuticamente.